ACT Biotech (Molecule Drug Assets) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $95M

ACT Biotech (Molecule Drug Assets) General Information

Description

Developer of molecule drugs for the treatment of cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • c/o NGN Capital, 369 Lexington Avenue
  • 17th floor
  • New York, NY 10017
  • United States
+1 (212)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Edding Genor Group Holdings Limited
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • c/o NGN Capital, 369 Lexington Avenue
  • 17th floor
  • New York, NY 10017
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ACT Biotech (Molecule Drug Assets) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Merger/Acquisition 19-Feb-2014 $95M Completed Startup
To view ACT Biotech (Molecule Drug Assets)’s complete valuation and funding history, request access »

ACT Biotech (Molecule Drug Assets) Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
ACT Biotech Corporation Majority
To view ACT Biotech (Molecule Drug Assets)’s complete investors history, request access »

Ready to get started?

Request a free trial

ACT Biotech (Molecule Drug Assets) FAQs

  • Where is ACT Biotech (Molecule Drug Assets) headquartered?

    ACT Biotech (Molecule Drug Assets) is headquartered in New York, NY.

  • What industry is ACT Biotech (Molecule Drug Assets) in?

    ACT Biotech (Molecule Drug Assets)’s primary industry is Drug Discovery.

  • Is ACT Biotech (Molecule Drug Assets) a private or public company?

    ACT Biotech (Molecule Drug Assets) is a Private company.

  • What is the current valuation of ACT Biotech (Molecule Drug Assets)?

    The current valuation of ACT Biotech (Molecule Drug Assets) is .

  • What is ACT Biotech (Molecule Drug Assets)’s current revenue?

    The current revenue for ACT Biotech (Molecule Drug Assets) is .

  • Who are ACT Biotech (Molecule Drug Assets)’s investors?

    ACT Biotech has invested in ACT Biotech (Molecule Drug Assets).

  • When was ACT Biotech (Molecule Drug Assets) acquired?

    ACT Biotech (Molecule Drug Assets) was acquired on 19-Feb-2014.

  • Who acquired ACT Biotech (Molecule Drug Assets)?

    ACT Biotech (Molecule Drug Assets) was acquired by Edding Genor Group Holdings Limited.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process